Okay, let's tackle this question. The question is about monoclonal antibodies used in Muckle-Wells syndrome. First, I need to recall what Muckle-Wells syndrome is. From what I remember, it's a type of autoinflammatory disease, part of the cryopyrin-associated periodic syndromes (CAPS). These conditions are caused by mutations in the NLRP3 gene, leading to overproduction of interleukin-1 beta (IL-1β).

Now, the treatment for CAPS typically targets IL-1β. The monoclonal antibodies used here would be against IL-1β or its receptor. The main drugs I know are anakinra (which is an IL-1 receptor antagonist), canakinumab (anti-IL-1β monoclonal antibody), and rilonacept (a fusion protein that inhibits IL-1β). Among these, canakinumab is a monoclonal antibody specifically targeting IL-1β. So the correct answer should be canakinumab.

Looking at the options, the correct answer is likely option C if the options follow a standard pattern. But since the options aren't provided, I need to make sure. The key here is that the question asks for a monoclonal antibody. Anakinra is a recombinant IL-1 receptor antagonist, not a monoclonal antibody. Rilonacept is a fusion protein, so it's not a monoclonal antibody either. So the only monoclonal antibody targeting IL-1β is canakinumab.

Now, for the wrong options: if the options include anakinra, that's incorrect because it's not a monoclonal antibody. If another option is a TNF inhibitor like adalimumab, that's for different conditions like rheumatoid arthritis, not CAPS. Similarly, drugs like tocilizumab (anti-IL-6) are used in other conditions. So the distractors would be other biologics not specific to IL-1β.

The clinical pearl here is that for CAPS, targeting IL-1β is crucial. Remembering that canakinumab is the monoclonal antibody against IL-1β used in these syndromes is key. The high-yield fact is that Muckle-Wells syndrome is a CAPS, treated with IL-1β inhibitors, specifically canakinumab as a monoclonal antibody.

**Core Concept**
Muckle-Wells syndrome is a rare autoinflammatory disorder caused by *NLRP3* gene mutations, leading to excessive interleukin-1β (IL-1β) production. Therapeutic strategies target IL-1β to suppress inflammation.

**Why the Correct Answer is Right**
Canakinumab is a human monoclonal antibody that directly neutralizes IL-1β, a key cytokine in the pathogenesis of Muckle-Wells syndrome. By inhibiting IL-1β signaling, it reduces systemic inflammation, preventing symptoms like urticaria, hearing loss, and amyloidosis. It is FDA-approved for cryopyrin-associated periodic syndromes (CAPS), including Muckle-Wells.

**Why Each Wrong Option is Incorrect**
**Option A:** Anakinra is an IL-1 receptor antagonist (not a monoclonal antibody) used for CAPS but binds to IL-1 receptors

✓ Correct Answer: A. Canakinumab